slides · global inventory
Traction
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,471
Current window 6,361-6,390
Pages 350
Rows per page 30
Slide type
6,361-6,390 of 10,471
17
D-Wave | Investor Presentation Deck | 28 slidesD-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
23
The slide uses a scientific publication as social proof and a log-log chart to demonstrate performance scaling.D-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · Action1 hit
25
The slide uses a circular graphic to emphasize the 99% uptime metric.D-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · Action1 hit
27
Includes footnotes regarding YOY growth consistency and ELOC liquidity.D-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · Action1 hit
17
The slide uses a background image of the product (EOS energy storage units) to frame the data blocks.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · SatisfactionLoop · Voice Of Customer1 hit
07
The slide uses a side-by-side comparison structure to detail the status and upcoming milestones for two distinct clinical programs.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
Includes before/after patient photos and comparative data against Mogamulizumab.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
Equillium | Investor Presentation Deck | 32 slidesEquillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
23
Includes visual longitudinal data (photos) and quantitative bar chart data.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide uses a consistent bar chart format for four distinct business lines, providing both historical annual data and recent quarterly performance.FGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations Beat · Financials1 hit
25
The slide uses a consistent color scheme where the most recent quarter (3Q23) is highlighted in a darker blue.FGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations Beat · Financials1 hit
04
The slide highlights clinical validation through trial count and patient numbers, alongside key product attributes.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Problem1 hit
09
The slide compares mPFS results against SOC-AURELIA and ELAHARE benchmarks.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
10
The slide outlines the methodology and validation of a clinical trial.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
Waterfall plot and spider plot used to visualize clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
13
The slide uses a before-after comparison structure for three specific patient cases (15B-01, 15B-15, 15B-17).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
14
Includes a Kaplan-Meier plot with a table comparing historical data to VIRO-15 trial results.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
17
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
18
Includes specific patient case reports (Pt #21A-06 and Pt #21A-04) showing tumor response metrics.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
19
Includes a bio for Benny Li, PhD, CEO of Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
20
The slide highlights the strategic partnership and the division of commercial rights between Genelux and Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
32
The slide uses two distinct chart types to show longitudinal dynamics (line chart) and best response (waterfall chart) for the CA-125 biomarker.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
33
The slide uses a dual-axis chart to correlate tumor size (SLD) and biomarker (CA-125) response to the Olvi-Vec intervention.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
35
The slide uses histology images and HALO infiltration histograms to demonstrate the mechanism of action and clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
36
The slide uses a combination of immunological data (ELISPOT) and clinical imaging data (SLD) to show causality between immune response and tumor shrinkage.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
18
The chart demonstrates a clear inverse relationship where the spike in HBI0101 cells corresponds to a rapid decline in dFLC levels, stabilizing around the 30-day mark.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
34
The slide uses a side-by-side comparison of two disease indications, each with a list of clinical outcomes and a bottom section showing relevant market competitors and patient incidence numbers.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
35
The chart illustrates clinical trial efficacy data for NXC-201.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
47
Slide contains three distinct data charts comparing IMX-110 against standard treatments in mouse models.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
48
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit